Home › Crohn's Disease › New York › New York City
Crohn's Disease clinical trials in New York City, NY
35 studies for Crohn's Disease are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
RecruitingPhase 2
- New York Gastroenterology Associates - Upper East Side /ID# 281767, New York
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
RecruitingPhase 3
- New York Gastroenterology Associates ( Site 0253), New York
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
RecruitingPhase 3
- NYU Langone Health - Inflammatory Bowel Disease Center (IBD) ( Site 5078), New York
- Weill Cornell Medical College, New-York Presbyterian Hospital ( Site 5079), New York
- New York Gastroenterology Associates ( Site 5013), New York
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
RecruitingPhase 4
- New York Gastroenterology Associates, New York
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RecruitingPhase 2
- Northwell Health-Lenox Hill Hospital /ID# 265527, New York
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center, New York
- Icahn School of Medicine at Mount Sinai, New York
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 2
- Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
- New York Gastroenterology Associates, New York
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 2/3
- Inflammatory Bowel Disease Center at NYU Langone, New York
- Weill Cornell Medical College, New York
- Lenox Hill Hospital, New York
- and 1 more
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
RecruitingPhase 3
- New York Gastroenterology Associates, New York
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
- Manhattan Clinical Research, LLC-Site Number: 8400069, New York
- NYU Langone Health-Site Number: 8400091, New York
- Columbia University Medical Center-Site Number: 8400138, New York
- and 2 more
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
- NYU Langone Health-Site Number: 8400091, New York
- Weill Cornell Medicine - NewYork-Presbyterian Hospital-Site Number: 8400040, New York
- New York Gastroenterology Associates-Site Number: 8400009, New York
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
- Icahn School of Medicine at Mount Sinai /ID# 254880, New York
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
RecruitingPhase 3
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
RecruitingPhase 4
- NYU Langone Health, New York
Standardized Microbiota Transplant Therapy in Crohn's Disease
RecruitingPhase 2
- NYU Langone Health, New York
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
- New York Gastroenterology Associates, New York
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RecruitingPhase 3
- Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC), New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center/New York Presbyterian, New York
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RecruitingPhase 3
- Weill Cornell Medicine, New York
Behavioral Therapy for Crohn's Disease
Recruiting
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Recruiting
- NYU Langone Health, New York
- Cornell University, New York
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RecruitingObservational study
- New York University, New York
Low Dose IL-2 for the Treatment of Crohn's Disease
RecruitingPhase 1/2
- Mount Sinai, New York
Autologous Stem Cell Transplant for Crohn's Disease
RecruitingPhase 2
- Icahn School of Medicine at Mount Sinai, New York
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
- Icahn School of Medicine at Mount Sinai /ID# 262216, New York
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
RecruitingPhase 3
- New York Presbyterian Hospital, New York
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
RecruitingPhase 2
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RecruitingPhase 3
- Columbia University Medical Center, New York-Presbyterian Hospital, New York
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
RecruitingPhase 4
- Columbia University Medical Center, New York
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
Recruiting
- Weill Cornell Medical College, New York
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RecruitingPhase 2
- Mirador Therapeutics Selected Site, New York
Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
RecruitingObservational studyHealthy volunteers welcome
- Icahn School of Medicine at Mount Sinai, New York
Treatment of Moderate to Severe Refractory Crohn's Disease
RecruitingPhase 1/2
- Mount Sinai Health Systems, New York
Helmsley 3.0: Abbreviated MRE
RecruitingObservational study
- NYU Langone, New York
About Crohn's Disease
Crohn's Disease can cause inflammation in any area from the mouth to the anus. Read about medicines, surgery or dietary management to treat symptoms.
More about Crohn's Disease on MedlinePlus
Crohn's Disease trials in other cities
- Boston, MA19 studies
- Miami, FL19 studies
- Cleveland, OH19 studies
- St. Louis, MO19 studies
- Tyler, TX17 studies
- Houston, TX17 studies
- Orlando, FL17 studies
- Atlanta, GA17 studies
- San Antonio, TX15 studies
- San Diego, CA15 studies
- Los Angeles, CA15 studies
- Colorado Springs, CO13 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.